Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lilotomab satetraxetan
- Development stage
- Unknown
- Lead developer
- Nordic Nanovector
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Lilotomab satetraxetan is a novel radioimmunoconjugate composed of a murine monoclonal antibody (lilotomab, formerly known as tetulomab or HH1) targeting the CD37 glycoprotein on mature human B cells, conjugated to the beta-emitting radionuclide lutetium‑177 via the chelator satetraxetan. It is designed for single-dose radioimmunotherapy in relapsed or refractory non-Hodgkin’s lymphoma (NHL), particularly follicular lymphoma and marginal zone lymphoma. The drug delivers targeted ionizing radiation to malignant B cells expressing CD37, providing cytotoxic effects while sparing most normal tissues. Developed by Nordic Nanovector, it has received orphan drug status in both the US and EU for follicular lymphoma and marginal zone B-cell lymphoma[2][4][5][7].
- Brand names
- Betalutin
- Other names
- Lutetium (177lu) lilotomab satetraxetanLutetium 177Lu lilotomab satetraxetanLutetium177Lu lilotomab satetraxetanLutetium-177Lu lilotomab satetraxetanLutetium-177-tetulomabLutetium177-tetulomabLutetium 177-tetulomab
02
Targets
CD37
Beyond the preview
Go deeper on lilotomab satetraxetan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lilotomab satetraxetan.